TRCT
FULC icon

Tower Research Capital (TRC)’s Fulcrum Therapeutics FULC Stock Holding History

Tower Research Capital (TRC)’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$50.4K Buy
6,567
+4,943
+304% +$45.9K ﹤0.01% 2732
2025
Q4 		$18.4K Sell
1,624
-286
-15% -$2.91K ﹤0.01% 3161
2025
Q3 		$17.6K Sell
1,910
-4,467
-70% -$32.3K ﹤0.01% 3423
2025
Q2 		$43.9K Sell
6,377
-1,955
-23% -$10.5K ﹤0.01% 3083
2025
Q1 		$24K Buy
8,332
+4,357
+110% +$16K ﹤0.01% 2799
2024
Q4 		$18.7K Sell
3,975
-24,145
-86% -$89.1K ﹤0.01% 3242
2024
Q3 		$100K Buy
28,120
+11,796
+72% +$87.5K ﹤0.01% 2229
2024
Q2 		$101K Buy
16,324
+6,473
+66% +$49K ﹤0.01% 2572
2024
Q1 		$93K Buy
9,851
+6,193
+169% +$55.3K ﹤0.01% 1866
2023
Q4 		$24.7K Sell
3,658
-1,589
-30% -$7.05K ﹤0.01% 3529
2023
Q3 		$23.3K Sell
5,247
-5,773
-52% -$25.2K ﹤0.01% 3236
2023
Q2 		$36.4K Buy
11,020
+5,100
+86% +$15K ﹤0.01% 2860
2023
Q1 		$17K Buy
5,920
+4,096
+225% +$36.7K ﹤0.01% 3629
2022
Q4 		$13K Sell
1,824
-289
-14% -$1.89K ﹤0.01% 3602
2022
Q3 		$17K Sell
2,113
-3,790
-64% -$27.1K ﹤0.01% 4063
2022
Q2 		$28K Buy
5,903
+5,239
+789% +$51.2K ﹤0.01% 3440
2022
Q1 		$16K Sell
664
-2,963
-82% -$41.9K ﹤0.01% 3751
2021
Q4 		$65K Buy
3,627
+3,093
+579% +$61.3K ﹤0.01% 2555
2021
Q3 		$15K Sell
534
-1,119
-68% -$21.2K ﹤0.01% 3972
2021
Q2 		$17K Buy
1,653
+633
+62% +$6.4K ﹤0.01% 4040
2021
Q1 		$12K Sell
1,020
-4,179
-80% -$51.7K ﹤0.01% 4259
2020
Q4 		$61K Sell
5,199
-8,356
-62% -$94.5K ﹤0.01% 2894
2020
Q3 		$107K Buy
13,555
+11,084
+449% +$133K ﹤0.01% 3105
2020
Q2 		$45K Buy
+2,471
New +$38.9K ﹤0.01% 3130
2019
Q4 		– Sell
-931
Closed -$6K – 3804
2019
Q3 		$6K Buy
+931
New +$10.3K ﹤0.01% 3214

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Tower Research Capital (TRC)'s FULC Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Fulcrum Therapeutics (FULC) stake by 304% in Q1 2026, buying an estimated $45.9K and bringing the position to 6,567 shares worth $50.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2732.

Tower Research Capital (TRC) first reported a position in FULC in Q3 2019 and has held it in 25 quarters since. The position peaked at $107K in Q3 2020. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • Tower Research Capital (TRC) held 6,567 shares of Fulcrum Therapeutics worth $50.4K as of Q1 2026.
  • Tower Research Capital (TRC) bought 4,943 Fulcrum Therapeutics shares in Q1 2026, an estimated $45.9K.
  • Fulcrum Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #2732 holding.
  • Tower Research Capital (TRC) first reported a position in Fulcrum Therapeutics in Q3 2019 and has held it in 25 quarters since.
  • Tower Research Capital (TRC)'s Fulcrum Therapeutics position peaked at $107K in Q3 2020.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.